Posted by Michael Wonder on 11 Dec 2023
Erasca granted FDA fast track designation for pan-RAF inhibitor naporafenib in patients with advanced NRAS mutated melanoma
11 December 2023 - First in class and best-in-class potential in NRAS mutated melanoma and other RAS/MAPK pathway altered solid tumours.
Erasca today announced that the US FDA has granted fast track designation to naporafenib in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma who have progressed on, or are intolerant to, an anti‑programmed death-1 (ligand 1) based regimen, and whose tumours contain an NRAS mutation.
